Navigation Links
Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

st $55 million at the end of 2013, inclusive of research funding from Shire but exclusive of funds arising from any additional new collaborations or partnerships, or other new sources. 
  • Revenues: Sangamo expects that revenues will be in the range of $20 to $24 million in 2013, inclusive of research funding from Shire.
  • Operating Expenses: Sangamo expects that operating expenses will be in the range of $46 to $50 million for 2013.
  • Conference Call
    Sangamo will host a conference call today, February 6, 2013 at 5:00 p.m. ET, which will be open to the public.  The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm.  The webcast replay will also be available for two weeks after the call. During the conference call, the Company will review these results, discuss other business matters, and provide guidance with respect to 2013. 

    The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 92659211.  For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 6, 2013 to midnight ET on February 13, 2013. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 92659211. 

    About Sangamo
    Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HI
    '/>"/>

    SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
    2. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
    3. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
    4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
    5. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
    6. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
    7. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
    8. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
    9. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
    10. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
    11. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
    (Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
    (Date:7/30/2015)... July 30, 2015  Unichem Pharmaceuticals ( USA ... of Hydrochlorothiazide tablets 25 mg 1000-count bottle to the ... precautionary measure due to the identification of a Clopidogrel ... The risk associated with mistakenly taking a ... increased probability of experiencing Clopidogrel,s side effects which include ...
    Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
    ... Ellman International, Inc., a New York based developer, manufacturer ... procedures, announced that Frank D. D,Amelio will join its ... (COO), Executive Vice President. "We are proud to welcome ... help guide the company,s continued growth," said Chief Executive ...
    ... This month, Minnesotans are recognized for their outstanding ... and for their donations of the blood component, plasma, ... Throughout September, Minnesota Gov. Tim Pawlenty is recognizing "Plasma ... to raise awareness for the rare, genetic diseases treated ...
    Cached Medicine Technology:Ellman International Announces Executive Team Hire 2Minnesotans Help Produce As Well As Benefit from Lifesaving Therapies 2
    (Date:7/31/2015)... ... July 31, 2015 , ... In the most recent ... Court in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini ... docket entry was made recording the minutes of the status conference, which was held ...
    (Date:7/31/2015)... ... July 31, 2015 , ... People love to feel like ... where price is an important factor to clients when choosing to purchase a ... the Preferred Producer Multi-Life Discount program, where advisers pass savings onto their clients. ...
    (Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error on ... by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, ... drug, biologic and device firms reduce manufacturing errors by 50 percent or more, ...
    (Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
    (Date:7/30/2015)... Miami, FL (PRWEB) , ... July 30, 2015 ... ... a new online program entitled " Lovetraction Lines ." It's for women interested ... in the men they desire. The course, which officially launched to the public ...
    Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
    ... real-time imaging and image guidance systems for use in,the operating room, will be holding its annual ... DATE: May ... 9:30 am, Eastern Daylight Time, LOCATION: ... 150 King Street West ...
    ... Using ... ImmunoCAP -, PORTAGE, Mich., May ... and Clinical Immunology revealed variations in,the results of three common allergy diagnostic ... specialists at,Mount Sinai School of Medicine, determined that the laboratory results from,two ...
    ... May 8 In March, AHIP,s Board of,Directors ... the,Medicare Advantage and Medicare Part D plan marketing ... issued its new regulations., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ... to ensure beneficiaries can rely on the,information being ...
    ... prolongs the life of these growth-driving molecules in breast ... Emory University,s Winship Cancer Institute. , The results are ... journal Molecular Cell. , Most breast cancers contain estrogen ... of the hormone estrogen. Their presence can determine whether ...
    ... May 8, 2008 People with diagnosed diabetes are nearly ... by arthritis hinders the successful management of both diseases, according ... released today by the Centers for Disease Control and Prevention ... kind to look at the relationship between arthritis and diabetes ...
    ... Neuroscientists at Johns Hopkins have discovered that mice ... exhibit a number of schizophrenia-like behaviors. The finding ... in the development of schizophrenia and related psychiatric ... for developing therapies. , The BACE1 enzyme, ...
    Cached Medicine News:Health News:Novadaq Technologies Notice of Annual Meeting 2Health News:Novadaq Technologies Notice of Annual Meeting 3Health News:Data Show Common Allergy Tests Are Not Interchangeable 2Health News:Data Show Common Allergy Tests Are Not Interchangeable 3Health News:Previously unseen switch regulates breast cancer response to estrogen 2Health News:New report: Arthritis is a potential barrier to physical activity for adults with diabetes 2Health News:Hopkins researchers discover new link to schizophrenia 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: